<qa>  What is the potential utility of PD 0332991 in the treatment of early stageA Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER Human epidermal growth factor receptor 2 HER2- breast cancer, to investigate whether the combination of PD 0332991 and anastrozole is able to: 1 improve the pathologic complete response rate when compared to the historical control of single agent aromatase inhibitors, 2 result in fewer patients with on therapy Ki6710 compared to historical control. 